DARPA launches $73M RAPIID program to develop synthetic blood

DARPA has launched the $73 million RAPIID program to create shelf-stable versions of plasma, platelets, and red blood cells for military use. The goal is to deploy dried blood products in the field by 2029, as about 90% of preventable battlefield deaths stem from hemorrhage and the critical transfusion window is 36 minutes.

• RAPIID program received $73 million for three blood components
• 90% of preventable battlefield deaths are due to hemorrhage
• Critical transfusion window is 36 minutes after injury
• Goal is dried blood products in the field by 2029